ArticleJournal of the National Cancer Institute2012
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Article in Journal of the National Cancer Institute, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.Future oncology (London, England) · 2014Pooled it
- CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Review
- CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Expert opinion on drug metabolism & toxicology · 2022Review
- ClinicalCancers · 2021Review
- Breast cancer recurrence in relation to antidepressant use.Cancer causes & control : CCC · 2016Article
- Germline oncopharmacogenetics, a promising field in cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2015Review
- Addressing phenoconversion: the Achilles' heel of personalized medicine.British journal of clinical pharmacology · 2015Review
- Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Journal of the National Cancer Institute · 2014Article
- Status of adjuvant endocrine therapy for breast cancer.Breast cancer research : BCR · 2014Review
- Personalizing health care: feasibility and future implications.BMC medicine · 2013Review
- Do we need another selective estrogen receptor modulator for the adjuvant treatment of breast cancer?Current oncology (Toronto, Ont.) · 2013Article
- Pharmacological management of depression in patients with cancer: practical considerations.Drugs · 2013Review
- Pharmacogenomics of breast cancer therapy: an update.Pharmacology & therapeutics · 2013Review
- Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.Breast cancer research and treatment · 2013Article
- Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.ISRN pharmacology · 2013Article
- Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.International journal of medical sciences · 2013Article
- Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Review
Corrections and comments
- Commented on by
- Commented on by
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22395645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.